/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novel anti-VEGF agent approved in China may reduce injection frequency

    Conbercept shows higher binding affinity, lower VEGF dissociation rate, longer clearance time

     

    Take-home message: Conbercept is an anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of wet age-related macular degeneration in China. Compared with agents used in the United States, it has a higher binding affinity, lower VEGF dissociation rate, and longer clearance time.

     

     

    Cleveland—Conbercept—an anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of wet age-related macular degeneration (AMD) in China—appears to have the same safety and efficacy profile of the anti-VEGF medications available in the United States, but may allow for reduced dosing frequency, according to Peter K. Kaiser, MD.

    “The Chinese company [Kanghong Biotech, Chengdu, China] that developed conbercept is now in discussion with the FDA and with the European Medicines Agency to bring this product to other countries,” said Dr. Kaiser, Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Cleveland.

    In case you missed it: #Dressgate redux

    “Hopefully, it will become an additional option to use in the future for treating wet AMD,” he added.

    Next: How it compares, differs

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results